SEC Form 4 · accession 0001179110-19-002643
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sammy Karam
Officer — Senior Vice President
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 5:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $75.90 | Feb 22, 2019 | A | 81,578 | A | Feb 22, 2020 | Feb 21, 2029 | Common shares | 81,578 | 81,578 | D |
Explanation of responses
- F1Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022.